	US 12,296,071 B2
	Functionalisation of medical devices
Rachel Zimet Pytel, Newton, MA (US); and Neal Robert Carty, Chicago, IL (US)
Assigned to CONVATEC TECHNOLOGIES INC., Las Vegas, NV (US)
Filed by ConvaTec Technologies Inc., Las Vegas, NV (US)
Filed on Dec. 29, 2021, as Appl. No. 17/564,673.
Application 17/564,673 is a continuation of application No. PCT/US2021/065471, filed on Dec. 29, 2021.
Claims priority of provisional application 63/132,213, filed on Dec. 30, 2020.
Prior Publication US 2022/0202999 A1, Jun. 30, 2022
Int. Cl. A61L 29/08 (2006.01); A61L 29/04 (2006.01); B05D 1/00 (2006.01); B05D 3/14 (2006.01); B05D 5/02 (2006.01)

CPC A61L 29/085 (2013.01) [A61L 29/049 (2013.01); B05D 1/62 (2013.01); B05D 3/147 (2013.01); B05D 3/148 (2013.01); B05D 5/02 (2013.01); A61L 2400/18 (2013.01); A61L 2420/02 (2013.01); B05D 2518/00 (2013.01)]

14 Claims

1. A method of modifying a medical device, the method comprising:

functionalizing a surface of the medical device using cold plasma,

wherein:

functionalizing the surface of the medical device using cold plasma comprises contacting the surface with cold plasma to provide a plasma-treated surface and performing cold plasma treatment at a temperature between 15° C. and 40° C.,

contacting the surface with cold plasma comprises introducing a monomer to cold plasma to create monomer plasma and applying the monomer plasma to the surface to provide the plasma-treated surface,

the method further comprises mixing the monomer with a precursor gas stream consisting of nitrogen gas,

functionalizing the surface using cold plasma comprises functionalizing the plasma-treated surface with a polymer, and

the polymer or the monomer is a polyalkylene glycol having a reactive end group.